Medtronic has reported positive results from a study of its MiniMed 780G automated insulin delivery system in addressing burdensome challenges of diabetes.

The data indicates the system’s ability in managing hyperglycemia and reducing night-time disruptions for people with type 1 diabetes.

Designed for use by type 1 diabetes patients, the MiniMed 780G system is intended for the continuous delivery of basal insulin at selectable rates and amounts.

The study focused on the dawn phenomenon, a common cause of elevated morning glucose levels.

A retrospective analysis of data from 6,026 patients showed that those switching from the MiniMed 770G to the MiniMed 780G experienced a significant reduction in morning glucose peaks.

The incidence of the dawn phenomenon dropped from 12.2% to 4.5%, and time in range improved from 87.7% to 91.4% between midnight and 6am.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Further data from 8,019 patients, including children under seven, indicated that the MiniMed 780G system’s automatic insulin adjustments every five minutes led to fewer overnight interruptions and better glucose control.

Night-time alerts decreased by 45%, and users gained an additional 30–36 minutes of uninterrupted sleep.

Currently, the MiniMed 780G system is available for individuals aged seven and older in more than 100 countries.

Medtronic is also developing the next version of the MiniMed 780G system to further ease diabetes management.

Medtronic Diabetes chief medical officer Robert Vigersky said: “For those living with type 1 diabetes, dawn phenomenon can be a stressful occurrence that feels out of one’s control.

“The introduction of the MiniMed 780G system has made it easier to maintain target glucose range with less effort to protect against hyperglycemia. It has been an absolute gift for my patients who have struggled with stubborn highs throughout their diabetes journey.”

In 2022, Health Canada issued a licence to Medtronic’s MiniMed 780G insulin pump system.